218 related articles for article (PubMed ID: 20509930)
1. Antiproliferative effect of growth hormone-releasing hormone (GHRH) antagonist on ovarian cancer cells through the EGFR-Akt pathway.
Guo J; Schally AV; Zarandi M; Varga J; Leung PC
Reprod Biol Endocrinol; 2010 May; 8():54. PubMed ID: 20509930
[TBL] [Abstract][Full Text] [Related]
2. Cellular mechanisms of growth inhibition of human endometrial cancer cell line by an antagonist of growth hormone-releasing hormone.
Zhao L; Yano T; Osuga Y; Nakagawa S; Oishi H; Wada-Hiraike O; Tang X; Yano N; Kugu K; Schally AV; Taketani Y
Int J Oncol; 2008 Mar; 32(3):593-601. PubMed ID: 18292936
[TBL] [Abstract][Full Text] [Related]
3. Impact of Axis of GHRH and GHRH Receptor on Cell Viability and Apoptosis of the Placental Choriocarcinoma Cell Line.
Liu AX; Zhang D; Zhu YM; Gao HJ; Jiang JY; Hu XL; Lv PP; Leung PC; Huang HF
Curr Mol Med; 2016; 16(3):299-311. PubMed ID: 26917260
[TBL] [Abstract][Full Text] [Related]
4. Combination of GHRH antagonists and docetaxel shows experimental effectiveness for the treatment of triple-negative breast cancers.
Seitz S; Rick FG; Schally AV; Treszl A; Hohla F; Szalontay L; Zarandi M; Ortmann O; Engel JB; Buchholz S
Oncol Rep; 2013 Jul; 30(1):413-8. PubMed ID: 23624870
[TBL] [Abstract][Full Text] [Related]
5. Growth hormone-releasing hormone antagonists abolish the transactivation of human epidermal growth factor receptors in advanced prostate cancer models.
Muñoz-Moreno L; Arenas MI; Carmena MJ; Schally AV; Prieto JC; Bajo AM
Invest New Drugs; 2014 Oct; 32(5):871-82. PubMed ID: 25000999
[TBL] [Abstract][Full Text] [Related]
6. Antagonists of growth hormone-releasing hormone (GHRH) reduce prostate size in experimental benign prostatic hyperplasia.
Rick FG; Schally AV; Block NL; Nadji M; Szepeshazi K; Zarandi M; Vidaurre I; Perez R; Halmos G; Szalontay L
Proc Natl Acad Sci U S A; 2011 Mar; 108(9):3755-60. PubMed ID: 21321192
[TBL] [Abstract][Full Text] [Related]
7. The effect of GHRH antagonists on human glioblastomas and their mechanism of action.
Pozsgai E; Schally AV; Zarandi M; Varga JL; Vidaurre I; Bellyei S
Int J Cancer; 2010 Nov; 127(10):2313-22. PubMed ID: 20162575
[TBL] [Abstract][Full Text] [Related]
8. Antagonists of growth hormone-releasing hormone inhibit growth of androgen-independent prostate cancer through inactivation of ERK and Akt kinases.
Rick FG; Schally AV; Szalontay L; Block NL; Szepeshazi K; Nadji M; Zarandi M; Hohla F; Buchholz S; Seitz S
Proc Natl Acad Sci U S A; 2012 Jan; 109(5):1655-60. PubMed ID: 22307626
[TBL] [Abstract][Full Text] [Related]
9. Growth hormone-releasing hormone antagonists inhibit growth of human ovarian cancer.
Papadia A; Schally AV; Halmos G; Varga JL; Seitz S; Buchholz S; Rick F; Zarandi M; Bellyei S; Treszl A; Szalontay L; Lucci JA
Horm Metab Res; 2011 Oct; 43(11):816-20. PubMed ID: 22009378
[TBL] [Abstract][Full Text] [Related]
10. The effect of a novel antagonist of growth hormone releasing hormone on cell proliferation and on the key cell signaling pathways in nine different breast cancer cell lines.
Pozsgai E; Schally AV; Hocsak E; Zarandi M; Rick F; Bellyei S
Int J Oncol; 2011 Oct; 39(4):1025-32. PubMed ID: 21701777
[TBL] [Abstract][Full Text] [Related]
11. Inhibitory effects of antagonists of growth hormone-releasing hormone on growth and invasiveness of PC3 human prostate cancer.
Muñoz-Moreno L; Arenas MI; Schally AV; Fernández-Martínez AB; Zarka E; González-Santander M; Carmena MJ; Vacas E; Prieto JC; Bajo AM
Int J Cancer; 2013 Feb; 132(4):755-65. PubMed ID: 22777643
[TBL] [Abstract][Full Text] [Related]
12. Essential role of p21/waf1 in the mediation of the anti-proliferative effects of GHRH antagonist JMR-132.
Volakaki AA; Lafkas D; Kassi E; Schally AV; Papavassiliou AG; Kiaris H
J Mol Endocrinol; 2008 Nov; 41(5):389-92. PubMed ID: 18765563
[TBL] [Abstract][Full Text] [Related]
13. Growth hormone-releasing hormone antagonist inhibits the invasiveness of human endometrial cancer cells by down-regulating twist and N-cadherin expression.
Wu HM; Huang HY; Schally AV; Chao A; Chou HH; Leung PC; Wang HS
Oncotarget; 2017 Jan; 8(3):4410-4421. PubMed ID: 28032599
[TBL] [Abstract][Full Text] [Related]
14. Novel GHRH antagonists suppress the growth of human malignant melanoma by restoring nuclear p27 function.
Szalontay L; Schally AV; Popovics P; Vidaurre I; Krishan A; Zarandi M; Cai RZ; Klukovits A; Block NL; Rick FG
Cell Cycle; 2014; 13(17):2790-7. PubMed ID: 25486366
[TBL] [Abstract][Full Text] [Related]
15. Dose-dependent growth inhibition in vivo of PC-3 prostate cancer with a reduction in tumoral growth factors after therapy with GHRH antagonist MZ-J-7-138.
Heinrich E; Schally AV; Buchholz S; Rick FG; Halmos G; Mile M; Groot K; Hohla F; Zarandi M; Varga JL
Prostate; 2008 Dec; 68(16):1763-72. PubMed ID: 18729085
[TBL] [Abstract][Full Text] [Related]
16. Novel antagonists of growth hormone-releasing hormone inhibit growth and vascularization of human experimental ovarian cancers.
Klukovits A; Schally AV; Szalontay L; Vidaurre I; Papadia A; Zarandi M; Varga JL; Block NL; Halmos G
Cancer; 2012 Feb; 118(3):670-80. PubMed ID: 21751186
[TBL] [Abstract][Full Text] [Related]
17. Prognosis in human glioblastoma based on expression of ligand growth hormone-releasing hormone, pituitary-type growth hormone-releasing hormone receptor, its splicing variant receptors, EGF receptor and PTEN genes.
Mezey G; Treszl A; Schally AV; Block NL; Vízkeleti L; Juhász A; Klekner A; Nagy J; Balázs M; Halmos G; Bognár L
J Cancer Res Clin Oncol; 2014 Oct; 140(10):1641-9. PubMed ID: 24878932
[TBL] [Abstract][Full Text] [Related]
18. The growth hormone-releasing hormone (GHRH) antagonist JV-1-36 inhibits proliferation and survival of human ectopic endometriotic stromal cells (ESCs) and the T HESC cell line.
Annunziata M; Grande C; Scarlatti F; Deltetto F; Delpiano E; Camanni M; Ghigo E; Granata R
Fertil Steril; 2010 Aug; 94(3):841-9. PubMed ID: 19524226
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of estrogen receptor positive and negative breast cancer cell lines with a growth hormone-releasing hormone antagonist.
Seitz S; Hohla F; Schally AV; Moder A; Engel JB; Horn F; Varga J; Zarandi M; Ortmann O; Köster F; Buchholz S
Oncol Rep; 2008 Nov; 20(5):1289-94. PubMed ID: 18949435
[TBL] [Abstract][Full Text] [Related]
20. Synergistic inhibition of growth of lung carcinomas by antagonists of growth hormone-releasing hormone in combination with docetaxel.
Hohla F; Schally AV; Szepeshazi K; Varga JL; Buchholz S; Köster F; Heinrich E; Halmos G; Rick FG; Kannadka C; Datz C; Kanashiro CA
Proc Natl Acad Sci U S A; 2006 Sep; 103(39):14513-8. PubMed ID: 16983095
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]